PT - JOURNAL ARTICLE AU - Tian, Yuan AU - Xing, Rui AU - Zhou, Jing AU - Qiao, Juanli AU - Liu, Zhaojun AU - Gu, Liankun AU - Zhang, Baozhen AU - Lu, Youyong AU - Deng, Dajun TI - Gene-Specific Common Deletion Regions and Detection of Gene Copy Number Deletion AID - 10.1101/2021.09.16.21263412 DP - 2022 Jan 01 TA - medRxiv PG - 2021.09.16.21263412 4099 - http://medrxiv.org/content/early/2022/05/12/2021.09.16.21263412.short 4100 - http://medrxiv.org/content/early/2022/05/12/2021.09.16.21263412.full AB - A feasible method to detect somatic copy number deletion (SCND) of tumor suppressor genes is still absent up to date. To overcome the obstacle of SCND detection, we analyzed genomic coordinates of gene deletion fragments using the Catalogue Of Somatic Mutation In Cancer (COSMIC) datasets. Interstitial base-resolution deletion/fusion coordinates for CDKN2A were extracted from published articles and our whole genome sequencing (WGS) datasets. The results showed that estimated common deletion regions (CDRs) were observed in many tumor suppressor genes, such as ATM, CDKN2A, FAT1, miR31HG, PTEN, and RB1 in the SNP array-based COSMIC datasets. A 5.1-kb base-resolution CDR could be identified in >90% cancer samples by sequencing. Using the true CDKN2A CDR as a PCR target, a multiplex quantitative PCR assay P16-Light was programmed to detect CDKN2A gene copy number with a lower detection limit of 20%. P16-Light was further confirmed with WGS as the gold standard among cancer tissue samples from 139 patients. In conclusion, CDRs are common in many tumor suppressor genes. The 5.1-kb CDKN2A CDR was found in >90% cancers containing CDKN2A deletion. The CDKN2A CDR was used a potential target for developing the P16-Light assay to detect CDKN2A SCND and amplification for routine clinical practices.Competing Interest StatementDD, YT, JZ, and ZL are the creators for the pending patent "A quantitative method for detection of human CDKN2A gene copy number using a primer set and their applications" (PCT/CN2019/087172; WO2020228009).Funding StatementThis work was supported by the Beijing Natural Science Foundation (grant number 7181002 to D.J.D.); Capital's Funds for Health Improvement and Research (grant number 2018-1-1021 to D.J.D.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institution Review Board of Peking University Cancer Hospital & Institute approved this study and was carried out in accordance with the principles outlined in the Declaration of Helsinki. Informed consent was obtained from each patient prior to their inclusion in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetailed information on the base-resolution interstitial common deletion region in the CDKN2A gene in 110 cancer samples and other data were provided in Supplementary Data files 1-14.CDRcommon deletion regionDHPLCdenaturing high performance liquid chromatographyGCgastric carcinomaLOHloss of heterozygosityMSImicrosatellite instabilityOMIMthe Online Mendelian Inheritance in ManSCNDsomatic copy number deletionSMsurgical marginTCGAThe Cancer Genome AtlasWGSwhole genome sequencing